Genmab (NASDAQ:GMAB) Stock

GENMAB A/S -SP ADR

Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS

A recent episode of &#8220;<a href="https://www.youtube.com/watch?v=L6398lZQHDk">The Ramsey Show</a>&#8221; took a sharp turn when a caller shared how his mother took out credit cards in his name after he and his brother bought her a home.
<h2 class="wp-block-heading">Mom Living In A Home Her Sons Bought, Son Holding The Bag</h2>
The caller, 27, explained that after his divorce, he was emotionally vulnerable and agreed to co-sign loans so his mom could buy the home she was living in. He and his brother put the mortgage in their names because his mom had <a href="https://www.benzinga.com/money/best-mortgage-lenders-for-poor-credit">poor credit</a>.
&#8220;She sucks blood off of her sons,&#8221; said Dave Ramsey after hearing the details. &#8220;She's a parasite. It's a horrible thing to say about your mother. I'm so sorry. Just an observation.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
The caller added that his mom makes minimal income and hasn't disclosed how much she earns. Meanwhile, she continues to make minimum payments on roughly $20,000 in credit card debt, all taken out under her son&#8217;s name.
"She's paying the mortgage," the caller said, but added that he constantly worries she'll stop. "I'm just waiting for the day that I get a call that, ‘Hey, your payment's due.'"
<h2 class="wp-block-heading">Selling The Home To Save The Marriage</h2>
Ramsey warned the caller that if he didn't take action quickly, this financial arrangement would result in deeper personal losses.
His advice? Sell the house. <a href="https://www.benzinga.com/money/best-ways-to-pay-off-credit-card-debt">Pay off all the credit cards</a>. Then, give his mom half of whatever equity remains. &#8220;You can go set yourself up a life with that,&#8221; he suggested.
Trending: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
Ramsey even gave him the script for the difficult conversation: &#8220;Mom, I love you, and I&#8217;ve done more for you than I should have, and I put myself and my future family in jeopardy because of you, and you continue to misbehave with this. My bills are not being paid, you&#8217;re destroying my credit and my future. We&#8217;re selling the house. Little brother, if you don&#8217;t want to sell it, you can buy me out.&#8221;
Ramsey also made it clear that the brother, who co-owns the home, should either buy him out or step aside. &#8220;If he doesn&#8217;t want to sell the house, then it&#8217;s going to be a civil court action and the judge is going to demand that the partnership be dissolved by the selling of the house,&#8221; Ramsey said.
&#8220;We&#8217;re selling the house. I&#8217;m not asking—we&#8217;re telling you. This is what we&#8217;re doing,&#8221; Ramsey added.
&#8220;This is saving your marriage, by the way,&#8221; Ramsey&#8217;s co-host, Jade Warshaw, said. The caller had just gotten married a month earlier, and this situation could become a major wedge. &#8220;Your wife is not going to sit around and let your mom be the reason that she&#8217;s not in her new house,&#8221; Warshaw added.
Read Next:
<ul class="wp-block-list">
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>
Image: Shutterstock

Personal Finance

'She's A Parasite,' Says Ramsey To A Caller Who Bought Their Mom The Family Home—Then She Took Out Credit Cards In His Name

INAB

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Tutor Perini (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) has outperformed the market over the past 5 years by 11.66% on an annualized basis producing an average annual return of 24.73%. Currently, Tutor Perini has a market capitalization of $2.05 billion. 
Buying $1000 In TPC: If an investor had bought $1000 of TPC stock 5 years ago, it would be worth $2,906.58 today based on a price of $38.89 for TPC at the time of writing.
<h3>Tutor Perini's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749167111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In Tutor Perini 5 Years Ago Would Be Worth This Much Today

Sterling Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) has outperformed the market over the past 5 years by 64.11% on an annualized basis producing an average annual return of 77.18%. Currently, Sterling Infrastructure has a market capitalization of $5.94 billion. 
Buying $100 In STRL: If an investor had bought $100 of STRL stock 5 years ago, it would be worth $1,771.69 today based on a price of $195.24 for STRL at the time of writing.
<h3>Sterling Infrastructure's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749166275_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

STRL

$100 Invested In Sterling Infrastructure 5 Years Ago Would Be Worth This Much Today

Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) has outperformed the market over the past 5 years by 12.84% on an annualized basis producing an average annual return of 25.91%. Currently, Rhythm Pharmaceuticals has a market capitalization of $4.21 billion. 
Buying $100 In RYTM: If an investor had bought $100 of RYTM stock 5 years ago, it would be worth $318.94 today based on a price of $66.18 for RYTM at the time of writing.
<h3>Rhythm Pharmaceuticals's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749165311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RYTM

Here's How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years

Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) has outperformed the market over the past 10 years by 8.89% on an annualized basis producing an average annual return of 19.78%. Currently, Sprouts Farmers Market has a market capitalization of $16.32 billion. 
Buying $100 In SFM: If an investor had bought $100 of SFM stock 10 years ago, it would be worth $613.02 today based on a price of $166.77 for SFM at the time of writing.
<h3>Sprouts Farmers Market's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749164417_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Sprouts Farmers Market Stock In The Last 10 Years

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) CEO Alex Karp expects the&nbsp;artificial intelligence&nbsp;arms race between the U.S. and China to have one winner.
Karp, on Thursday&#8217;s episode <a target="_blank" href="https://www.cnbc.com/2025/06/05/palantir-karp-ai-dangerous-china.html" rel="noreferrer noopener">of CNBC&#8217;</a>s &#8220;Squawk on the Street,&#8221; expressed his concerns regarding AI&#8217;s dangers while acknowledging its positive and negative consequences.
The stock is down amid reports indicating that some Republicans are criticizing the Trump administration&#8217;s deal with the company.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45800099" rel="noreferrer noopener">Palantir CEO Alex Karp Refutes &#8216;Ridiculous&#8217; Surveillance Reports, Says Company Is &#8216;Winning&#8217;</a>
He had previously voiced aggressive efforts required by countries to develop more advanced AI models.
Karp said that no other economy in the world has corporate leaders as adaptable, tech-savvy, and open to innovation while still rooted in deep industry expertise. He added that Western allies, including those in Europe, must take notes from this approach.
He denied reports indicating that the company surveilled Americans to help the Trump administration gather data on Americans.
Palantir Technologies stock surged 435% in the last 12 months.
Reportedly, the Trump administration <a target="_blank" href="https://www.benzinga.com/news/contracts/25/05/45702431/palantir-stock-gains-as-trump-expands-companys-role-in-us-government-agencies" rel="noreferrer noopener">has&nbsp;recently expanded</a> the company&#8217;s&nbsp;work across the federal government.
Since Trump took office, Palantir bagged over $113 million in contracts (new and additional funds from existing), excluding the $795 million Department of Defense contract.
Price Action: PLTR stock closed lower by 7.77% at $119.91 on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45801143" target="_blank" rel="noreferrer noopener">Palantir Stock Falls As GOP Lawmakers Push Back On Government Surveillance Deal</a></li>
</ul>
Photo by slyellow via Shutterstock

Movers

Tech

Media

PLTR

Palantir CEO Warns US-China AI Race Will Have One Winner, Urges West To Keep Up

Interparfums (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPAR#NASDAQ">IPAR</a>) has outperformed the market over the past 20 years by 4.53% on an annualized basis producing an average annual return of 12.81%. Currently, Interparfums has a market capitalization of $4.39 billion. 
Buying $1000 In IPAR: If an investor had bought $1000 of IPAR stock 20 years ago, it would be worth $10,353.03 today based on a price of $136.66 for IPAR at the time of writing.
<h3>Interparfums's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749163517_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IPAR

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

Offerings

DOGZ

Dogness International Files For Resale Of Up To 1.2M Class A Common Shares By Selling Shareholders

ITT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITT#NYSE">ITT</a>) has outperformed the market over the past 5 years by 5.96% on an annualized basis producing an average annual return of 19.04%. Currently, ITT has a market capitalization of $12.20 billion. 
Buying $1000 In ITT: If an investor had bought $1000 of ITT stock 5 years ago, it would be worth $2,308.83 today based on a price of $149.82 for ITT at the time of writing.
<h3>ITT's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749162611_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning ITT Stock In The Last 5 Years

Piper Sandler (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PIPR#NYSE">PIPR</a>) has outperformed the market over the past 5 years by 15.93% on an annualized basis producing an average annual return of 29.0%. Currently, Piper Sandler has a market capitalization of $4.22 billion. 
Buying $1000 In PIPR: If an investor had bought $1000 of PIPR stock 5 years ago, it would be worth $3,628.92 today based on a price of $257.00 for PIPR at the time of writing.
<h3>Piper Sandler's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749161711_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PIPR

$1000 Invested In Piper Sandler 5 Years Ago Would Be Worth This Much Today

In the current market session, Garrett Motion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>) share price is at $10.15, after a 0.20% increase. Moreover, over the past month, the stock fell by 10.65%, but in the past year, went up by 13.03%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1749160832_0.png" alt="Past Year Chart" />

<h3>Garrett Motion P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Garrett Motion has a lower P/E than the aggregate P/E of 17.31 of the Automobile Components industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1749160832_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

A Look Into Garrett Motion Inc's Price Over Earnings

Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) has outperformed the market over the past 15 years by 15.05% on an annualized basis producing an average annual return of 26.96%. Currently, Cintas has a market capitalization of $92.31 billion. 
Buying $100 In CTAS: If an investor had bought $100 of CTAS stock 15 years ago, it would be worth $3,580.28 today based on a price of $228.62 for CTAS at the time of writing.
<h3>Cintas's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749160820_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTAS

$100 Invested In Cintas 15 Years Ago Would Be Worth This Much Today

Space stocks are rising in Thursday&#8217;s after-hours session amid an escalation of a public dispute between SpaceX&#8217;s Elon Musk <a href="https://www.benzinga.com/news/politics/25/06/45800612/trump-says-musk-has-trump-derangement-syndrome-as-battle-over-bill-heats-up-had-a-great-relationship-dont-know-if-we-will-anymore">and President Donald Trump</a>.
What Happened: Musk and Trump are throwing jabs on their respective social media platforms spurred by the former&#8217;s disapproval of a large tax bill being pushed by Trump. 
In a Truth Social <a href="https://truthsocial.com/@realDonaldTrump/posts/114632206992330264">post</a> Thursday afternoon, Trump said the easiest way to cut spending is to get rid of Musk&#8217;s government subsidies and contracts. 
Musk quickly <a href="https://x.com/elonmusk/status/1930718684819112251">responded</a> with a post on X, indicating that SpaceX would immediately start decommissioning its Dragon spacecraft, which is currently the only option the U.S. has for carrying crew members to the International Space Station. 
NASA press secretary Bethany Stevens chimed in on the dispute, noting that NASA will continue to work with Trump to carry out his vision for the future of space. 
&#8220;We will continue to work with our industry partners to ensure the President's objectives in space are met,&#8221; Stevens <a href="https://x.com/NASASpox/status/1930728558558900435?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1930728558558900435%7Ctwgr%5Ee06d105bd2067e7db775e61b4af3ebf6faa7e713%7Ctwcon%5Es1_&amp;ref_url=https%3A%2F%2Fwww.cnbc.com%2F2025%2F06%2F05%2Fmusk-trump-spacex-dragon-nasa.html">said</a> in an X post.
Space stocks appear to be rallying in response to the news as investors are optimistic the spat could create more opportunities for other space companies. 
Rocket Lab Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>), which has multiple <a href="https://www.benzinga.com/news/contracts/25/05/45434506/rocket-lab-gets-nasa-contract-to-launch-aspera-astrophysics-mission">contracts</a> with NASA, saw its shares rise 5.22% in Thursday&#8217;s after-hours session, while AST SpaceMobile Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares climbed nearly 3% at last check.
AST SpaceMobile is one of Jeff Bezos&#8217; Blue Origin's top customers. The companies signed a deal&nbsp;in November 2024 for the launch of up to 45 satellites. A Scotiabank analyst <a href="https://www.benzinga.com/news/space/25/06/45776611/ast-spacemobile-stock-climbs-after-analyst-flags-potential-investment-from-amazons-jeff-bezos">speculated this week</a> that the relationship between the two companies could get even stronger in the near future. 
Shares of heavily-shorted Virgin Galactic Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) were also up nearly 15% in after-hours at the time of writing.
The dispute between Musk and Trump comes about two weeks after Trump <a href="https://www.benzinga.com/general/space/25/05/45532125/l3harris-stock-moves-higher-after-being-named-in-golden-dome-missile-defense-system">announced</a>&nbsp;the architecture for a $175 billion Golden Dome missile defense system. The system will feature next-generation technologies, including &#8220;space-based sensors and interceptors&#8221; and &#8220;a lot&#8221; of American companies will be involved, according to Trump. 
The tax bill, referred to as Trump&#8217;s &#8220;big, beautiful bill&#8221; is expected to include $175 billion for the Golden Dome project.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/06/45804512/trump-musk-feud-gets-ugly-etfs-exposed-with-tesla-caught-in-the-crossfire">Trump-Musk Feud Gets Ugly: ETFs Exposed With Tesla Caught In The Crossfire</a></li>
</ul>
Photo: courtesy of Rocket Lab.

SPACE

After-Hours Center

ASTS

RKLB

SPCE

Rocket Lab, AST SpaceMobile, Virgin Galactic Shares Are Rising After Hours: What's Going On?

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) stock traded down 14.3% to $284.70 on Thursday, the company's second-biggest percentage loss in more than a year and the biggest market cap loss in company history. The decline was<a href="https://www.benzinga.com/news/politics/25/06/45800612/trump-says-musk-has-trump-derangement-syndrome-as-battle-over-bill-heats-up-had-a-great-relationship-dont-know-if-we-will-anymore" target="_blank" rel="noopener"> caused by an escalated feud between</a> CEO Elon Musk and President Donald Trump.
What Happened: Tesla's market cap fell by a company record $152 billion, taking the company out of the $1 trillion market capitalization club. This move comes after Musk <a href="https://www.benzinga.com/news/25/05/45635854/elon-musk-disappointed-with-trumps-big-beautiful-bill-says-it-undermines-the-work-that-the-doge-team-is-doing" target="_blank" rel="noopener">publicly criticized</a> Trump's "Big Beautiful Bill."
Comments made by Trump in a press interview and by Musk and Trump on social media accounts escalated the battle, with people picking sides in a war of words between two of the world&#8217;s most influential voices.
Musk has been vocal about the projected increase in the national debt from the new spending bill.
"Congress is spending America into bankruptcy!" the Tesla CEO tweeted.
Trump posted a series of messages on his Truth Social account speaking out against Musk.
"I don't mind Elon turning against me, but he should have done so months ago. This is one of the Greatest Bills ever presented to Congress," Trump <a href="https://truthsocial.com/@realDonaldTrump/posts/114632555927229642">posted</a>.
The president said the bill will put the country "on a path of greatness."
Another <a href="https://truthsocial.com/@realDonaldTrump/posts/114632205177163456">post </a>had Trump saying that he asked Musk to leave the White House as he was "wearing thin." The president said he removed Musk's EV mandate, which "forced everyone to buy electric cars that nobody else wanted."
"And he just went CRAZY!"
Trump also <a href="https://truthsocial.com/@realDonaldTrump/posts/114632206992330264">suggested </a>that terminating government subsidies and contracts with Musk would be one way to save money.
Musk <a href="https://x.com/elonmusk/status/1930698237650026675">said </a>the president&#8217;s comments on the EV mandate are "an obvious lie" in a tweet. The Tesla and SpaceX CEO also suggested that he will <a href="https://x.com/elonmusk/status/1930718684819112251">decommission </a>the Dragon spacecraft in response to Trump's threat on subsidies. The Dragon spacecraft was recently used to bring two stranded astronauts home from the International Space Station.
Musk also <a href="https://x.com/elonmusk/status/1930685402631053403">asked </a>if it was time to create a new political party in America that represents the "80% in the middle." With over 1.1 million votes in, 82% had voted yes, suggesting a third-party option to the Democratic and Republican parties.
Escalating the feud further, Musk <a href="https://x.com/elonmusk/status/1930703865801810022">tweeted </a>that the "really big bomb" is that Trump is in the Epstein files, a reference to the list of people associated with convicted sex offender Jeffrey Epstein.
Benzinga reached out to the White House for comment on Musk's accusation and did not hear back.
Musk also <a href="https://x.com/elonmusk/status/1930722828481098043">suggested </a>that Trump's tariffs "will cause a recession in the second half" of 2025.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul class="wp-block-list">
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Tesla Stock Falls: Shares of the electric vehicle company suffered their second-largest fall year-to-date on Thursday, narrowly beaten by a 15.4% drop on March 10.
That March 10 drop was the largest percentage loss for Tesla shares in five years. The drop came as Musk's role in the White House expanded, and he said he planned to stay involved for another year. The stock had dropped in several sessions around that time amid tariff fears and concerns that Musk's political activism was damaging the Tesla brand.
While this marks Tesla&#8217;s largest market cap drop, it is also shy of the largest percentage drop in 2025 and all time.
The largest single-day percentage drop for Tesla stock was on Sept. 8, 2020, when it fell 21.1% after not being selected as a member of the S&amp;P 500 Index. The stock would later be added to the index.
Tesla stock fell 19.3% on Jan. 13, 2012 after two key departures were announced, as <a href="https://www.cnn.com/2020/09/08/investing/tesla-stock-plunge">reported </a>by CNN.
The good news for Tesla stock could be its history of rebounds after big drops. After shares fell 15.4% on March 10, 2025, the stock rose 3.8% the following day. After the record 21.1% drop on September 8, 2020, Tesla stock rose 10.9% the next day.
Tesla stock has traded between $167.42 and $488.54 over the last year, and it is now down 24.9% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45795080/whatever-you-think-of-elon-musk-you-must-support-his-fight-against-the-big-beautiful-bill-says-black-swan-author-nassim-taleb">&#8216;Whatever You Think Of Elon Musk, You Must Support His Fight Against The Big Beautiful Bill,&#8217; Says &#8216;Black Swan&#8217; Author Nassim Taleb</a></li>
</ul>
Image created using photos from Shutterstock.

Politics

Management

TSLA

Musk Vs. Trump: Tesla Suffers Record $152B One-Day Crash As CEO Warns Tariffs 'Will Cause A Recession'

Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) has outperformed the market over the past 15 years by 12.18% on an annualized basis producing an average annual return of 24.09%. Currently, Saia has a market capitalization of $6.75 billion. 
Buying $100 In SAIA: If an investor had bought $100 of SAIA stock 15 years ago, it would be worth $2,597.71 today based on a price of $253.45 for SAIA at the time of writing.
<h3>Saia's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749159917_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SAIA

Here's How Much You Would Have Made Owning Saia Stock In The Last 15 Years

General

HWBK

Hawthorn Bancshares Authorize The Repurchase Of Up To $10.0M  In Market Value Of The Company's Common Stock

Petco Health and Wellness Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) released its first-quarter results after Thursday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/06/n45802282/petco-health-wellness-company-inc-reports-first-quarter-2025-financial-results">details in the report. </a>
The Details: Petco Health and Wellness reported quarterly losses of four cents per share, which met the analyst consensus estimate. Quarterly revenue came in at $1.49 billion, missing the Street estimate of $1.5 billion and down from revenue of $1.53 billion from the same period last year.
Read Next:<a href="https://www.benzinga.com/markets/market-summary/25/06/45798808/trump-announces-china-trade-talks-tesla-stock-slumps-whats-driving-markets-thursday?utm_source=articleShare"> Trump Announces China Trade Talks, Tesla Stock Slumps: What&#8217;s Driving Markets Thursday?</a>
Petco reported: 
<ul class="wp-block-list">
<li>Net sales of $1.5 billion decreased 2.3% year-over-year in line with the company&#8217;s first quarter outlook.</li>
<li>Comparable sales decreased 1.3% year-over-year.</li>
<li>Gross profit margin expanded approximately 30 basis points to 38.2% as a percentage of net sales.</li>
</ul>
&#8220;We are pleased to deliver first quarter earnings results ahead of our guidance and to reaffirm our outlook for fiscal 2025, which now incorporates the impact of tariffs. This performance is a testament to the execution of our nearly 30,000 team members and the resilience of the category in which we operate,&#8221; said Joel Anderson, Petco&#8217;s CEO.
WOOF Price Action: According to data from<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw"> Benzinga Pro</a>, Petco stock was down 10.77% at $3.23 at publication during Thursday's extended trading. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/social-media/25/06/45749596/the-viral-student-loan-solution-people-cant-stop-talking-about?utm_source=articleShare">Elon Musk&#8217;s Optimus Could Herald The Biggest Industry In History, Billionaire Investor Marc Andreessen Says</a></li>
</ul>
Photo: Shutterstock

Earnings

WOOF

Petco Stock Drops After Q1 Revenues Miss: Details

Sekisui House (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SKHSY#OTC">SKHSY</a>) GAAP EPS for Q1 2025 JPY 51.48 Down from JPY 77.80 YoY; Revenue JPY 894,044M Up from 777,052M YoY.

Earnings Misses

SKHSY

Sekisui House GAAP EPS for Q1 2025 JPY 51.48 Down from JPY 77.80 YoY; Revenue JPY 894,044M Up from 777,052M YoY.

Kadant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAI#NYSE">KAI</a>) has outperformed the market over the past 5 years by 10.79% on an annualized basis producing an average annual return of 23.86%. Currently, Kadant has a market capitalization of $3.81 billion. 
Buying $1000 In KAI: If an investor had bought $1000 of KAI stock 5 years ago, it would be worth $2,858.22 today based on a price of $323.55 for KAI at the time of writing.
<h3>Kadant's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749159021_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Kadant Stock In The Last 5 Years

Press Releases

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

Comments

Genmab

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL